Circulating complement levels and C3 glomerulopathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Kidney transplant in patients with C3 glomerulopathy.Clinical kidney journal · 2025
   Review
2. C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation.Frontiers in nephrology · 2024
   Review
3. X-linked C1GALT1C1 mutation causes atypical hemolytic uremic syndrome.European journal of human genetics : EJHG · 2023
   Article
4. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.International journal of molecular sciences · 2020
   Review
5. C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.Case reports in nephrology and dialysis
   Article
6. Peripheral Blood Lymphocyte Subsets and Clinical Parameters in Patients Undergoing Renal Biopsy.Kidney diseases (Basel, Switzerland)
   Article

Corrections and comments

• Comment on
  Defining the complement biomarker profile of C3 glomerulopathy.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as